Get the Stockscreener App
1.68
0.59%
-0.01
After Hours:
1.74
0.06
+3.57%
Aldeyra Therapeutics Inc stock is traded at $1.68, with a volume of 4.54M.
It is down -0.59% in the last 24 hours and down -69.23% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.69
Open:
$1.71
24h Volume:
4.54M
Relative Volume:
1.69
Market Cap:
$101.11M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.9798
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-9.19%
1M Performance:
-69.23%
6M Performance:
-67.94%
1Y Performance:
-69.32%
1-Day Range:
$1.68
$1.87
1-Week Range:
$1.67
$1.8762
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.68 | 101.71M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics pays off $15 million outstanding borrowings, terminates Hercules credit facilitySEC filing - marketscreener.com
Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit FacilitySEC Filing - tradingview.com
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility - tipranks.com
Aldeyra Therapeutics repays $15 million Hercules loan and ends credit facility - Investing.com
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Aldeyra pays off $15M loan, terminates Hercules credit facility - tradingview.com
Aldeyra (NASDAQ: ALDX) pays off $15M Hercules loan, extends runway - Stock Titan
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Malaysian Reserve
INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP - businesswire.com
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therap - gurufocus.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - GlobeNewswire Inc.
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - businesswire.com
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - bastillepost.com
Aldeyra (NASDAQ: ALDX) grants CEO 1.88M options and bonus units - Stock Titan
Aldeyra Therapeutics Sued for Securities Fraud - National Today
Lawsuit Filed Against Aldeyra Therapeutics Over Clinical Trial Inconsistencies - National Today
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Class Action Lawsuit Filed Against Aldeyra Therapeutics - National Today
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact ... - bdtonline.com
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for - GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the Aldeyra Therapeutics, Inc. Class Action - marketscreener.com
Rosen Law Firm Files Securities Class Action Against Aldeyra Therapeutics - National Today
Value Recap: Can Aldeyra Therapeutics Inc maintain sales growth2026 Technical Patterns & Fast Gain Swing Trade Alerts - baoquankhu1.vn
ROSEN, LEADING INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc. Investors – ALDX - The AI Journal
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Sees Large Increase in Short Interest - MarketBeat
ALDX Should I Buy - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
ALDX Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Aldeyra Therapeutics (ALDX) price target decreased by 22.41% to 7.65 - MSN
ALDX Investor News: Losses Reported for Aldeyra Therapeutics - National Today
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), ... - bdtonline.com
Aug EndMonth: Is Aldeyra Therapeutics Inc stock trending bullish2026 Momentum Check & Advanced Technical Analysis Signals - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-03-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ALDX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation - accessnewswire.com
Vanguard realignment reports 0 ALDX shares after disaggregation (ALDX) - Stock Titan
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation | NDAQ:ALDX | Press Release - stockhouse.com
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky - GlobeNewswire
ALDX Investor News: If You Have Suffered Losses in Aldeyra - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - accessnewswire.com
Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - chartmill.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - markets.financialcontent.com
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):